Beatriz Serrano1, Laia Alemany2, Patricia Alonso de Ruiz3, Sara Tous4, Marcus Aurelho Lima5, Laia Bruni6, Asha Jain7, Gary M Clifford8, You Lin Qiao9, Thomas Weiss10, F Xavier Bosch11, Silvia de Sanjosé12. 1. Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: bea.iconcologia@gmail.com. 2. Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain; CIBER Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain. Electronic address: lalemany@iconcologia.net. 3. Hospital General de México, México. Electronic address: ruizalonso01@aol.com. 4. Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: stous@iconcologia.net. 5. Hospital Dr. Hélio Angotti, Uberaba, Brazil. Electronic address: lapc@mednet.com.br. 6. Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: lbruni@iconcologia.net. 7. Cancer Prevention and Relief Society, Raipur, India. Electronic address: dr.ashajain@smsaraipur.co.in. 8. International Agency for Research on Cancer, Lyon, France. Electronic address: clifford@iarc.fr. 9. National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: qiaoy@cicams.ac.cn. 10. Global Health Outcomes, Merck & Co., Inc., West Point, PA USA. Electronic address: thomas_weiss@merck.com. 11. Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain. Electronic address: x.bosch@iconcologia.net. 12. Unit of Infections and Cancer. Catalan Institute of Oncology, Barcelona, Spain; CIBER Epidemiología y Salud Pública, CIBERESP, Barcelona, Spain. Electronic address: s.sanjose@iconcologia.net.
Abstract
BACKGROUND: We estimated the potential impact of an investigational 9-valent human papillomavirus (HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) in HPV-related cervical disease in Brazil, Mexico, India and China, to help to formulate recommendations on cervical cancer prevention and control. METHODS: Estimations for invasive cervical cancer (ICC) were based on an international study including 1356 HPV-positive cases for the four countries altogether, and estimations for precancerous cervical lesions were extracted from a published meta-analysis including 6 025 HPV-positive women from the four mentioned countries. Globocan 2012 and 2012 World Population Prospects were used to estimate current and future projections of new ICC cases. RESULTS: Combined proportions of the 9 HPV types in ICC were 88.6% (95%CI: 85.2-91.3) in Brazil, 85.7% (82.3-88.8) in Mexico, 92.2% (87.9-95.3) in India and 97.3% (93.9-99.1) in China. The additional HPV 31/33/45/52/58 proportions were 18.8% (15.3-22.7) in Brazil, 17.6% (14.2-21.2) in Mexico, 11.3% (7.5-16.1) in India and 11.9% (7.5-17.2) in China. HPV6 and 11 single types were not identified in any of the samples. Proportion of the individual 7 high risk HPV types included in the vaccine varied by cytological and histological grades of HPV-positive precancerous cervical lesions. HPV 16 was the dominant type in all lesions, with contributions in low grade lesions ranging from 16.6%(14.3-19.2) in Mexico to 39.8% (30.0-50.2) in India, and contributions in high grade lesions ranging from 43.8% (36.3-51.4) in Mexico to 64.1% (60.6-67.5) in Brazil. After HPV 16, variations in other majors HPV types were observed by country, with an under representation of HPV 18 and 45 compared to ICC. CONCLUSION: The addition of HPVs 31/33/45/52/58 to HPV types included in current vaccines could increase the ICC preventable fraction in a range of 12 to 19% across the four countries, accounting the 9-types altogether 90% of ICC cases. Assuming the same degree of efficacy of current vaccines, the implementation of the 9-valent HPV vaccine in Brazil, Mexico, India and China would substantially impact on the reduction of the world cervical cancer burden.
BACKGROUND: We estimated the potential impact of an investigational 9-valent human papillomavirus (HPV) vaccine (HPVs 6/11/16/18/31/33/45/52/58) in HPV-related cervical disease in Brazil, Mexico, India and China, to help to formulate recommendations on cervical cancer prevention and control. METHODS: Estimations for invasive cervical cancer (ICC) were based on an international study including 1356 HPV-positive cases for the four countries altogether, and estimations for precancerous cervical lesions were extracted from a published meta-analysis including 6 025 HPV-positive women from the four mentioned countries. Globocan 2012 and 2012 World Population Prospects were used to estimate current and future projections of new ICC cases. RESULTS: Combined proportions of the 9 HPV types in ICC were 88.6% (95%CI: 85.2-91.3) in Brazil, 85.7% (82.3-88.8) in Mexico, 92.2% (87.9-95.3) in India and 97.3% (93.9-99.1) in China. The additional HPV 31/33/45/52/58 proportions were 18.8% (15.3-22.7) in Brazil, 17.6% (14.2-21.2) in Mexico, 11.3% (7.5-16.1) in India and 11.9% (7.5-17.2) in China. HPV6 and 11 single types were not identified in any of the samples. Proportion of the individual 7 high risk HPV types included in the vaccine varied by cytological and histological grades of HPV-positive precancerous cervical lesions. HPV 16 was the dominant type in all lesions, with contributions in low grade lesions ranging from 16.6%(14.3-19.2) in Mexico to 39.8% (30.0-50.2) in India, and contributions in high grade lesions ranging from 43.8% (36.3-51.4) in Mexico to 64.1% (60.6-67.5) in Brazil. After HPV 16, variations in other majors HPV types were observed by country, with an under representation of HPV 18 and 45 compared to ICC. CONCLUSION: The addition of HPVs 31/33/45/52/58 to HPV types included in current vaccines could increase the ICC preventable fraction in a range of 12 to 19% across the four countries, accounting the 9-types altogether 90% of ICC cases. Assuming the same degree of efficacy of current vaccines, the implementation of the 9-valent HPV vaccine in Brazil, Mexico, India and China would substantially impact on the reduction of the world cervical cancer burden.
Authors: Jane R Montealegre; Indu Varier; Christina G Bracamontes; Laura M Dillon; Martial Guillaud; Andrew G Sikora; Michele Follen; Karen Adler-Storthz; Michael E Scheurer Journal: Ethn Health Date: 2017-09-04 Impact factor: 2.772
Authors: Maxime Bonjour; Hadrien Charvat; Eduardo L Franco; Marion Piñeros; Gary M Clifford; Freddie Bray; Iacopo Baussano Journal: Lancet Public Health Date: 2021-04-15
Authors: Monika Wagner; Liga Bennetts; Harshila Patel; Sharon Welner; Silvia de Sanjose; Thomas W Weiss Journal: Infect Agent Cancer Date: 2015-04-28 Impact factor: 2.965
Authors: G Orlando; S Bianchi; M M Fasolo; F Mazza; E R Frati; G Rizzardini; A Matteelli; N Zanchetta; A Amendola; E Tanzi Journal: J Prev Med Hyg Date: 2017-12-30
Authors: Xavier Castellsagué; Kevin A Ault; F Xavier Bosch; Darron Brown; Jack Cuzick; Daron G Ferris; Elmar A Joura; Suzanne M Garland; Anna R Giuliano; Mauricio Hernandez-Avila; Warner Huh; Ole-Erik Iversen; Susanne K Kjaer; Joaquin Luna; Joseph Monsonego; Nubia Muñoz; Evan Myers; Jorma Paavonen; Punnee Pitisuttihum; Marc Steben; Cosette M Wheeler; Gonzalo Perez; Alfred Saah; Alain Luxembourg; Heather L Sings; Christine Velicer Journal: Papillomavirus Res Date: 2016-03-14
Authors: C Signorelli; A Odone; V Ciorba; P Cella; R A Audisio; A Lombardi; L Mariani; F S Mennini; S Pecorelli; G Rezza; G V Zuccotti; A Peracino Journal: Epidemiol Infect Date: 2017-04-27 Impact factor: 4.434